Fichier PDF

Partage, hébergement, conversion et archivage facile de documents au format PDF

Partager un fichier Mes fichiers Convertir un fichier Boite à outils PDF Recherche PDF Aide Contact



Nanobiotix corporate January 2016 .pdf



Nom original: Nanobiotix_corporate_January_2016.pdf
Titre: Nanobiotix corporate January 2016
Auteur: emilie.coquard

Ce document au format PDF 1.4 a été généré par PDFCreator Version 1.7.2 / GPL Ghostscript 9.10, et a été envoyé sur fichier-pdf.fr le 09/03/2016 à 16:44, depuis l'adresse IP 82.242.x.x. La présente page de téléchargement du fichier a été vue 8516 fois.
Taille du document: 3 Mo (34 pages).
Confidentialité: fichier public




Télécharger le fichier (PDF)









Aperçu du document


Corporate
Presentation

2016

IMPORTANT NOTICE AND DISCLAIMER
Important: You must read the following before continuing. By accessing the information in this document and by attending any oral presentation made in
conjunction with this document you represent, warrant and undertake that you have read and agreed to comply with the contents of this Notice and Disclaimer.
This document, the oral presentation accompanying this document and any questions and answers session following the oral presentation (the “Presentation”) have been
prepared by Nanobiotix (the “Company”) solely for selected qualified institutional buyers (“QIBs”) as defined in Rule 144A of the Securities Act of 1933, as amended (the
“Securities Act”) for information purposes. The information contained in the Presentation is strictly confidential and may not be copied, reproduced, distributed or disseminated,
directly or indirectly, in whole or in part, by or to any person.
This document does not purport to contain comprehensive or complete information about the Company and is qualified in its entirety by the business, financial and other
information that the Company is required to publish in accordance with the rules, regulations and practices applicable to companies listed on Euronext Paris, including the risk
factors, in the Company’s Document de référence (Registration Document), registered by the AMF on January 27, 2014 under no. R.14-0002, and in any other periodic report,
which are available free of charge on the websites of the Company (www.nanobiotix.fr) and the AMF (www.amf-france.org). Certain figures and numbers appearing in this
document have been rounded. Consequently, the total amounts and percentages appearing in tables and elsewhere may not necessarily equal the sum of the individually
rounded figures, amounts or percentages.
No representation, warranty or undertaking, express or implied, is made as to the accuracy, completeness or appropriateness of the information and opinions contained in this
Presentation, or its use for any purpose, and no reliance should be placed on any information or opinions contained in it. The Company, its subsidiaries, its advisors and
representatives accept no responsibility for and shall not, under any circumstance, be held liable for any loss or damage that may arise from the use of this Presentation or the
information or opinions contained in it. In particular, this document contains information on the use of the Company products and its competitive position. This information has
been drawn from various sources or from the Company’s own estimates which may not be accurate and thus no reliance should be placed on such information. Any
prospective investors must make their own investigation and assessments and consult with their own advisers concerning any evaluation of the Company and its prospects, and
this Presentation, or any part of it, may not form the basis of or be relied on in connection with any investment decision.
All statements in the Presentation other than statements of historical fact are or may be deemed to be forward-looking statements. These forward looking statements can be
identified by the use of forward looking terminology, including the terms “will”, “should”, “develop”, “development”, “strategy”, “targeting”, “expanding”, “mid term”, “medium term”
“enable”, “anticipated”, “expected”, “benefits”, “expand”, “target”, “promising”, “plan”, “evolve”, “optimize”, “prepare”, “pipeline”, “grow”, “time”, “timeline”, “endpoints”, “potential”,
“route”, “trend”, “grow”, or other forward looking vocabulary and terminology, or by discussions of strategy, plans, objectives, goals, expectations, hopes, future events,
operations or intentions, estimates and projections with respect to the Company’s products and markets for its products. These forward-looking statements are not guarantees of
future performance and involve a number of known and unknown risks and uncertainties. These risks and uncertainties, and other factors, could adversely affect the outcome of
the forward looking statements, and actual results could differ materially from those contemplated in the statements. As a result, you are cautioned not to rely on such forwardlooking statements. Forward-looking statements speak only as to the date of this document and the Company expressly disclaims any obligation or undertaking to update or reissue any forward-looking statements contained in this Presentation.
The information contained in this Presentation is provided as of the date of this document only and may be updated, supplemented, revised or amended, and thus such
information may be subject to changes at any time. Neither the Company, nor its advisors, nor any other person is under any obligation to update the information, statements or
opinions contained in this Presentation.
This Presentation does not constitute or form any part of any offer to sell, or the solicitation of an offer to buy or subscribe for, any shares or securities in the Company in the
United States or in any other jurisdiction. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S.
Securities Act of 1933, as amended. The Company has not registered, and does not intend to register, any offering of its securities in the United States.

Presentation 2016

2

NanoXray positioned to become a standard of care
in oncology
First in class radioenhancer that could change everything without
changing anything
1
Lead product has shown to be both safe and efficacious in “ultimate tumor case”
Derisking the all concept
Allows for higher dose/efficacy without increasing toxicity

2
Versatile application to target the majority of the oncology market
Broad pipeline in six major indications with potential expansion in most of solid tumors
NanoXray can easily be combined with chemotherapy, immuno-oncology …

3
Disruptive innovation compatible with care in current hospital setting
Disruptive innovation in existing and well structured radiotherapy market
Does not require change of the existing infrastructure, protocol, training

4

Several key milestones in the coming 12 months
Sarcoma Phase II/III interim data mid 2016 and CE mark end of 2016
Data in Liver cancer Phase I/II starting H2 2016
Results of Phase I/II H&N cancer H1 2016

Presentation 2016

3

Nanobiotix applies physics to cancer treatment
Molecules
(drugs and biologics)

Nanotechnology
supports the effect of
molecules

Nano-object becomes
the active principle

1940’s

1980’s

2000

Today

Chemistry

Biology

Nanosized drug
delivery system

New therapeutic
tools based on
physics

50nm

e.g. Mechlorethamine

e.g. Herceptin

e.g. NanoXray

e.g. Doxil

Physics
Biology
Presentation 2016

4

Company Snapshot
General description
Nanobiotix is a French company headquartered in Paris and
has US affiliate in Cambridge
Nanobiotix develops enhanced radiotherapy through
nanotechnology to treat cancer

History
2003: Founding of Nanobiotix
2012: $57m plus royalties collaboration with PharmaEngine
for NBTRX3 in Asia
2012: Listing on NYSE Euronext Paris

Market cap on NYSE Euronext Paris is € 230 m*
2014: Positive safety and efficacy results of NBTRX3 in STS
Well funded: €25m of cash & cash equivalents**
2015: Start of phase I/II NBTXR3 in liver mets and HCC

NanoXray
Nanobiotix develops innovative nanoparticle technology
dedicated to the local treatment of cancer
Nanoparticles interact with radiotherapy and maximize the
effect of radiotherapy within tumors
Lead product NBTXR3 targets several major cancers
NBTXR3 first registration study in STS (EU, Asia, Can) has
started targeting 2016 for first approval

Presentation 2016

* As of December 2015 (Bloomberg); ** As of end 2015 H1

5

Nanobiotix targets one of the largest oncology market:
radiotherapy
Conventional radiotherapy
60%* of cancer patients receive
radiotherapy as a local
treatment

TUMOR

Destroys any cancer cell at the
right dose…
… but important limitations due to
toxicity on healthy tissues
Energy deposition

Xray track

How to improve the energy dose within the tumor without increasing the
dose in healthy tissues?
Source: * RADIATION THERAPY EQUIPMENT – A global strategic business report 08/06
http://cology4u.blogspot.com/2011/06/cancer-radiotherapy.html

Presentation 2016

6

Solution:
NanoXray maximizes Xray absorption in the tumor
NanoXray Technology / key features

50nm

1
Nanosized to
enter cell

2
Designed to
strongly
absorb Xrays

3
Designed to be
non-toxic

HfO2 nanoparticles; electron microscopy picture

50 nanometer HfO2* particles were
chosen because they have the best ratio
for X-ray absorption and non toxicity

NanoXray is a true radioenhancer with a physical mode of action
6 patent families protecting concept and products until 2029 minimum
Note: *HfO2: Hafnium Oxide

Presentation 2016

7

NanoXray has a purely physical mode of action
Radiotherapy alone
Dose

Usual dose
delivered in the cell

Interaction of Xray with water generates
electrons

Radiotherapy with NanoXray
Dose

9X Dose*
around
nanoparticles
Interaction with Hafnium is higher and
generates much more electrons

NanoXray is a true radioenhancer with a physical mode of action
*Note: Dose enhancement determined by montecarlo simulation (CEA Saclay, France)

Presentation 2016

8

Versatile application for the majority of the
oncology market
15 million new cancer patients*

1 Major medical benefits
Of which 60%** receive radiotherapy
as a local treatment

Other markets

and markets

> 3m
patients

3

Opens new indications
for radiotherapy with
Nanoxray

Increase efficacy of
radiotherapy with Nanoxray

6m
patients

2
Additional benefits
and markets
Reduces dose (toxicity)
of radiotherapy with Nanoxray

Radiotherapy becoming nanoRadiotherapy:
Universal type mode of action that could target millions of patients
Positioned across all oncology
Potential synergies with other approaches, cytotoxic, targeted, Immuno
Fit in practice: Use standard RTx equipment and protocols
Presentation 2016

Sources:
* World Health Organization.
** RADIATION THERAPY EQUIPMENT – A global strategic business report 08/06.
http://cology4u.blogspot.com/2011/06/cancer-radiotherapy.html

9

NBTXR3 lead product

Crystalline
HfO2

coating

NBTXR3 has been developed for Intratumoral (IT) and selective Intra-Arterial
(IA) injection
Products manufactured in a qualified
and validated GMP process
Price for manufacturing within the
standard range of a chemical product

Only one injection for all radiotherapy
treatment
Fit in standard of care: No change in
protocol or equipment

Presentation 2016

10

NANOBIOTIX has a broad development pipeline strong
expected news flow
Indication
Soft tissue
sarcoma

Neo
adjuvant
and
definitive
treatment
NTBXR3
water
formulation
for IT and IA

EU

HCC

EU

Head and neck
cancer

NBTXR3 gel
formulation

Presentation 2016

IND

EU, CAN, ASIA

Liver metastasis

EU

PI/II PII/III

RA

Expected news flow
Interim data mid 2016; CE mark YE 2016

Multiple data in 3 populations starting
H2 2016

First complete data H1 2016

Rectum cancer

ASIA

PharmaEngine trial

Prostate cancer

USA

IND just granted

Other solid
tumors and
indications (i.e.
GBM, breast
cancer)

Post
surgery

Preclinical

Other solid
tumors and
indications (i.e.
GBM, breast
cancer, NSCLC)

First NanoXray applications are focused on
improving RTx efficacy

> 3m
patients

6m
patients

11

Clinical development in Soft Tissue Sarcoma

Patient population:
Soft Tissue Sarcoma of the extremities*
and trunk wall
Locally advanced soft tissue sarcoma,
newly diagnosed or relapsed tumor:
Unresectable tumor or unfeasible
carcinological surgical resection

Unmet medical need for locally advanced soft tissue sarcoma
Presentation 2016

* arms and legs

12

Current medical practice in locally advanced soft
tissue sarcoma has poor outcome for patients
Pre-operative radiotherapy is a standard of care to render surgery feasible
Pathological Response (pR), Tumor shrinkage, R0 surgery are key to improve Overall
Survival of patients with locally advanced tumors
* Reference: D. Roberge et al.
Radiotherapy and Oncology 97 (2010)
404–407

D. Roberge et. al. Radiotherapy
and Oncology 97 (2010) 404–7

Tumor shrinkage (mean)

0%

pR

50%

npR

59%

Note: 24% pats with margin less than 1mm

Unmet medical need: current radiation treatment has less than 8%
Pathological Complete Response, without significant tumor shrinking
Presentation 2016

13

PI/II Soft Tissue Sarcoma trial flowchart

D1 NBTXR3
administration

D2
1st RTx

Radiotherapy
25 x 2Gy

D37
end of RTx

D72-79
Surgery

D95-102
End of treatment

Patient registration

CT Scan

CT Scan

NBTXR3 injection feasibility
Primary endpoints

Safety evaluation
NBTXR3 dispersion and persistence

exploratory endpoint

RR (tumor shrinkage), pR, operability

NBTXR3 aims to improve cure chances through successful surgery
and complete response
Presentation 2016

protocol @ http://clinicaltrials.gov/ct2/show/NCT01433068?term=nanobiotix&rank=2

14

NBTXR3 primary endpoints achieved:
Safety & feasibility of the injection procedure
4 dose levels tested in various types of sarcomas:
Shapes
Size from 55ml to 3680ml tumor volume
Histology / structure
All ages and sex (excluding children)
Successful implementation of the intratumoral injection procedure
Single injection procedure and no other
change for patients or health professionals

Excellent systemic safety (few grade 1 AEs)
Excellent safety at Recommended Dose 10%
of tumor volume

Product has been shown easy to inject, safe regardless of the tumor
size and patient variability
Presentation 2016

15

Primary endpoints achieved:
dispersion and residency of NBTXR3 in the tumor

- 54 %

- 70 %

- 82%

Persistence of NBTXR3 during all sessions of RTx: optimal bioavailability over time
Presentation 2016

16

NBTXR3 / response
Radiotherapy alone*

Radiotherapy with NBTXR3

(Result from Literature*/not a direct comparator)
100
80
60

Disease
40
Progression
20

Stable
Disease

0
-20

Partial
Response

-40
Individual cases
(N=21)

Canter et al*
(N=25)

Le Grange et al
(N=55)
Borderline operable patients

NBTXR3
(N=21)
Non resectable patients

DP

20% (5)

2% (1)

5% (1)

SD

80% (20)

90% (50)

70% (15)

PR

-

8% (4**)

23% (5)

**all myxoid
Presentation 2016

17

NBTXR3 Shrinkage and pR evaluation
pathological Response

Radiotherapy alone
(Result from Literature*/not a direct comparator)

99%
pR Mean = 50%

74%
64%

Shrinkage Mean = 0%

Tumor shrinkage

20%

NBTXR3

-13% @ 2.5%
-40% @ 5%
-41% @ 10%

NBTXR3
-41% @ 20%

Presentation 2016

tumor shrinkage and pR increasing with
NBTXR3 volume
Large delta when comparing to
literature

* D. Roberge et. al. Radiotherapy and Oncology 97 (2010) 404–7

18

NBTXR3 Pathological response
and tumor volume evolution
Radiotherapy alone

Radiotherapy with NBTXR3

(Result from Literature*/not a direct comparator)
D. Roberge et. al. Radiotherapy
and Oncology 97 (2010) 404–7

tumor shrinkage (mean)

0%

pR

50%

npR

59%

Note: 24% pats with margin less than 1mm

NBTXR3 (level)

2,5%

5%

10%

20%

tumor shrinkage
(mean)

-13%

-40%

-41%

-41%

pR (mean)
npR

64%
67%

20%
67%

74%
88%

99%
99%

large surgery
margin

6/6

6/6

8/8

2/2

At 10% volume, the pathological Response was 74%
At 10% volume, the tumor shrinkage was -41%
tumor shrinkage increasing with NBTXR3 volume

Recommended
volume

All patients treated in the study had a wide surgical resection of the tumor
Recommended volume for PII/III
Presentation 2016

Note: npR : 100% pR in shrinked volume and pR in remaining volume

19

NBTXR3 worldwide development strategy
Fast track to CE mark and POC
Soft Tissue Sarcoma
Shortest pathway to market (CE mark) in EU,
CE mark targeted in 2016

Establishing the value of NBTXR3

Stand alone
dev

Stand alone
dev

pharmaEngine

Liver Cancers (Liver metastasis and HCC)
Maximize value through OS or PFS / short term end point

Expansion in multiple indications
and territories
H&N cancer
Prostate cancer (to be started)
Rectum cancer

Presentation 2016

Global development optimizing
i) time to market and ii) value
creation through multiple indications
and WW development

20

Phase II/III registration study in Soft Tissue Sarcoma
Study design STS phase II/III
Population: Patients with locally advanced soft tissue sarcoma of the extremity and trunk wall
Number of patients
Sites and countries

Multi center, open-label, randomised trial with active control
Test arm

156 patients
23 to 30 sites
12 countries

NBTXR3 with RTX 50Gy

Mid 2016
interim data of
104 patients

End points
1 Complete path response rate
(pCR)
2 Tumor shrinking rate and
operability

Randomization

EU, CAN, ASIA

1:1

Stratification population:
myxoid Lps vs others

End 2016
CE mark

RTX 50Gy

Progression free survival
Amputation rate

Comparator arm

QoL

pCR primary endpoint
evaluation

Presentation 2016

Implementation of guidelines for pathological response evaluation with:
International board including leaders from the US and EU
Centralized and blinded assessment reading of the treatment response

21

Next high-value market of NBTXR3 is liver cancer
Study design liver cancer phase I/II
Population: patients with liver cancers who need an alternative treatment when the standard of care (SOC) cannot be used or
does not exist
Number of patients
Sites and countries

Multi center, open-label, non-randomised trial

Phase I up to 40 patients
(IT and IA)
Phase II up to 150 patients
(3 arms)

End points
1 Safety (DTL)
2 Recommended dose
Safety (AE)
CR, PFS, OS (efficacy)
Biological markers
Feasibility of injection

Data points
Presentation 2016

First data H2
2016
Phase I/II in liver cancer will yield several data points on 3 different populations:
Interim safety and feasibility data, interim efficacy data and final data
22

Expanding value of NBTXR3 in an ongoing
head and neck cancer pilot study
Study design H&N cancer phase I/II
Population: Patients with locally advanced squamous cell carcinoma of the oral cavity or oropharynx
Number of patients
Sites and countries

Multi center, open-label, non-randomised trial
Part 1 (on going)

40 patients
(IT and IA)

4 dose levels: Age >65 and RTx
alone

3 sites
2 countries

Complete set of
data on first arm
H1 2016

Part 2 to be launch

End points

Adults; combo RTx and
chemotherapy (cisplatine)

1 Safety (DTL)
2 Recommended dose
Safety (AE)
ORR and CR (efficacy)
Local PFS and PFS (efficacy)

Head and neck (H&N) cancer patients
11% of H&N patients will receive RTx alone
35% will receive RTx plus chemotherapy

Feasibility of injection

Interim data

Presentation 2016

Intermediate results show the feasibility of the NBTXR3 injection
Good safety on both 5% and 10% dose levels
No leakage of the product surrounding tissues over time
23

Expanding value and development in the US of NBTXR3
with prostate cancer I/II study
Study design prostate cancer phase I/II
Population: patients with newly diagnosed intermediate and high risk prostate adenocarcinoma treated with androgen
deprivation
Number of patients
Sites and countries

US

PI 3 centers (US) : 2 arms; up
to 24 pts (IT)
PII : up to 20 pts per arm

End points
1 Safety (DTL)

Multi center, open-label, non-randomised trial
IND just granted

Phase I

Phase II

EBRT (24 pts)
Dose escaltion (5, 10, 17, 22%)
IT administration

EBRT 20 pts
at the recommended dose

Brachytherapy + EBRT (24 pts)
Dose escaltion (5, 10, 17, 22%)
IT administration

Brachytherapy + EBRT 20 pts
at the recommended dose

IND granted

2 Recommended dose
Safety (AE)
Feasibility of injection
LPFS, RR, OS

Safety and recommended dose

Safety @ recommended dose

Efficacy: RR, LPFS, biochemical failure, OS

biochemical failure

Data points
Presentation 2016

PI involving 3 reference centers in the US, timeline to be communicated
24

Financials and shareholders
Financials
(€ '000)
Operating revenue
Other revenue
Subsidies
Research tax credit
Total revenue
Cost of sales
R&D costs
General costs
Costs associated with payments in shares
Operating loss
Income from cash
Gross costs of debt
Net cost of debt
Other financial income
Other financial expenses
Pre-tax loss
Tax
Net loss
P&L in shareholder's equity
Foreign exchange translation adjustments
Global results
Diluted earnings per share

Shareholder breakdown
30 June 2015

30 June 2014

91
1,568
139
1,429

91
906
240
666

1,659

997


(6,124)
(2,848)
(559)


(3,362)
(1,785)
(54)

(7,872)

(4,203)

116
(4)

67
(28)

112

39

3
(16)


(2)

(7,773)

(4,166)





(7,773)

(4,166)

211
(4)

(113)


(7,567)

(4,280)

(1)

(0)

Positive cash balance of €25m as of 30 June 2015

Management
7%

Family offices
13%

42%

Free float

38%
Institutional investors

Analyst coverage
Gilbert Dupont (Fr) – Guillaume Cuvillier
CM-CIC Securities (Fr) – Arsène Guekam
Stifel (UK Office) – Michael King
Piper Jaffray & Co – Charles Duncan
Edison Research (UK) *– Dr Philippa Gardner

Funding secured to reach CE Mark for STS

Presentation 2016

25

Achievements and upcoming milestones
Achievements since 18 months
Positive safety and efficacy results of phase I/II
NBTRX3 trial in STS

Upcoming milestones
Interim data NBTRX3 pivotal – phase II/III trial
NBTRX3 CE mark for STS

Start of NBTRX3 pivotal – phase II/III trial in STS
Final data NBTRX3 phase I/II trial in H&N
Positive safety interim results of phase I/II
NBTRX3 trial in H&N cancer / 2 first level
Start of NBTRX3 phase I/II trial in liver
metastasis and HCC

Interim safety and feasibility data, interim efficacy
data of NBTRX3 phase I/II trial in liver
metastasis and HCC

Start of NBTRX3 phase I/II trial in rectum cancer
Initiation of PI/II prostate cancer trial
NBTRX3 clinical data in other indications
New program in Immuno Oncology

Nanobiotix has made significant progress in the development of their lead product
NBTRX3 since its IPO in 2012

Presentation 2016

26

NanoXray positioned to become a standard of care
in oncology
First in class radioenhancer that could change everything without
changing anything
1
Lead product has shown to be both safe and efficacious in “ultimate tumor case”
Derisking the all concept
Allows for higher dose/efficacy without increasing toxicity

2
Versatile application to target the majority of the oncology market
Broad pipeline in six major indications with potential expansion in most of solid tumors
NanoXray can easily be combined with chemotherapy, immuno-oncology …

3
Disruptive innovation compatible with care in current hospital setting
Disruptive innovation in existing and well structured radiotherapy market
Does not require change of the existing infrastructure, protocol, training

4

Several key milestones in the coming 12 months
Sarcoma Phase II/III interim data mid 2016 and CE mark end of 2016
Data in Liver cancer Phase I/II starting H2 2016
Results of Phase I/II H&N cancer H1 2016

Presentation 2016

27

Contacts

Laurent Levy

Philippe Mauberna

CEO
Laurent.levy@nanobiotix.com

CFO
philippe.mauberna@nanobiotix.com

www.nanobiotix.com

Appendix

Product pipeline targets most RTx applications

Lead product

+ gel
INTRA TUMORAL INJECTION
where access is appropriate

NBTXR3 IT & IA

POST SURGERY RADIOTHERAPY
Gel for Tumor bed deposition
during surgery

NBTXR3 TOPO

Local administration to optimally improve the therapeutic index by
delivering the product where needed only

INTRA VENOUS INJECTION
tumor or organ anatomy
access, staging

NBTX IV
Systemic administration when
local is not appropriate

NBTXR3 IT & IA
Targeted indications

• Soft tissue sarcoma
• Liver metastasis
• Head & neck tumors
• Oesophageal cancer
• Hepatocellular carcinoma • Rectal cancer

• Glioblastoma
• Prostate cancer
• Pancreatic cancer

Product Pipeline to fit all RTx practices and patient situations
Presentation 2016

30

Focused and Experienced Management Team
Covering all value chain in Product Development
Executive Board
Laurent Levy, CEO and Co-founder
Pioneer in nanomedicine, 20 years in nanobusiness
Leading roles in several nano-organizations (e.g. Vice
President ETP nanomedicine,)

Philippe Mauberna, Chief Financial Officer
Broad financial experience in the Life Sciences Industry
with successful EMEA operational project management in
Financial Effectiveness

Elsa Borghi, Chief Medical Officer
Successful track record in Research and Development
and registration of several oncology products at Sanofi

Bernd Mühlenweg, Chief Business Officer
Track record in partnering, licensing and M&A
Formerly with WILEX AG

Directors
Patrick Tricoli, VP Corporate Development, in charge
of US Affiliate
Broad experience in Pharmaceutical Industry Corporate
and R&D, with strong focus in international Business &
Partnering activities. Formerly with Sanofi.

Maija Hietava-Lorenzi, Senior Director QA
Broad experience in CMC as Qualified Person and as an
international inspector with World Health Organization.
Former key positions at Ark Therapeutics, Fit Biotech Plc
and Finnish Medicines Agency

Thierry Otin, Senior Director Manufacturing, Supply
Former Quality Site Manager (EU Sterile) at Roche and
before then, Head Pharmacist (Pharmaceutical Qualified
Person) and Quality Director at LFB Biotechnologies

Presentation 2016

Mikaela Dimitriu, VP Global Clinical Development
Former R&D Director in the Pharmaceutical Industry with
strong track record in implementation and management of
international Clinical studies in Oncology field

Agnès Pottier, Senior Director Discovery & IP
Expert in synthesis of nanomaterials
R&D leadership roles for more than a decade
Formerly with Rodhia

Sarah Gaubert, Director Communication & Public
Affairs
Former political advisor and communication for French
Ministers (healthcare, Education and research)
Former political advisor of French President

31

Supervisory Board

Supervisory Board
Laurent Condomine, Chairman of SB
Broad experience in Pharmaceutical Industry
Former Vice-President Business Development
AstraZeneca, responsible for: Group strategy,
mergers and acquisitions

Christope Douat, member of SB
Chairman of Medincell and President of Great North
Broad experience in capital venture
Formerly with Matignon Technologies, one of
Europe’s largest funds specialized in Medtech
Alumni of the Boston Consulting Group

Anne-Marie Graffin, member of SB
Over 20 years in the pharmaceutical industry
Former Executive Director Business Management and
Vice-President for Europe of Sanofi-Pasteur MSD

Dr. Alain Herrera, MD, member of SB
25 years of experience in the pharmaceutical industry
Strong focus in oncology drug development and
marketing
Former Head of the Oncology business at Sanofi-Aventis
for ten years
Former Hematologist Consultant at Antoine Beclere
Hospital

Enno Spillner, member of SB
14 years’ experience in the life science industry
CEO and CFO of 4SC AG, listed german biotech
company
Former Head of Finance and Managing Partner of
the German regional biotech venture fund, BioM AG

Presentation 2016

32

Strong IP
9 patent families, from which 6 are published, are protecting the concept and
products

Strong IP protection until 2029 at earliest
Presentation 2016

33

First product NBTXR3:
Billion+ Dollar Market Potential for Initial Indications
INDICATIONS WITH HIGH UNMET NEED NBTXR3

Target patient population in USA, Japan and EU top 5 for initial indications of the portfolio
Indication cancer specific

Indication organ specific (secondary cancer)

Incidence (‘000)

Incidence (‘000)

Advanced Prostate
Cancer

549,9

Colorectal Cancer

461,0

Pancreas Cancer

108,3

Head and Neck Cancer

108,3

Glioblastoma
Soft Tissue Sarcoma

518,0

Colorectal Cancer
Pancreas Cancer

461,0
108,3

Total (‘000)

Hepatocellular
Carcinoma
Esophageal Cancer

Breast cancer

1,087

97,3
57,1
300,0

34,8
21,8

Total (‘000)

Target patient population (‘000)
based on planned registration
studies

1,439

272,6

Target patient population (‘000)
based on planned registration
studies

NBTXR3 target more than 500,000
patients in top 7 countries.
Double by addition of Russia, Brazil,
China, India…

Incidence and target population ( 1): US, Japan, Top 5 EU markets. Ref Datamonitor ref. DMHC2593, DMHC 2467, DMHC 2339 and DMHC 2319 ; . ref. HC 00044-001, HC 00160001 and HC 00177-001.. Ref J. Gastro Intest Oncol, 2014, 5, 3 178-189. Ref NCCN 2014

Presentation 2016

34


Documents similaires


1 s2 0 s1533002811001071 main
new neck node atlas manuscript
greffe de cellules souches dans moelle
july 2018 presse release npg
planas silva et al 2008
hadrontherapy


Sur le même sujet..